Tech Company Financing Transactions
Alios BioPharma Funding Round
Alios BioPharma, operating out of South San Francisco, secured $8.4 million in investment from Novartis BioVenture Fund, Novo Ventures and Roche Venture Fund.
Transaction Overview
Company Name
Announced On
2/9/2009
Transaction Type
Venture Equity
Amount
$8,400,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
260 East Grand Ave. 2nd Floor
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferona).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lawrence Blatt
Chief Scientific Officer
Leonid Beigelman
Founder
John Donovan
Browse more venture capital transactions:
Prev: 2/9/2009: 7 Billion People venture capital transaction
Next: 2/9/2009: SolFocus venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to record all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs